Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC reduced its position in Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) by 27.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,312 shares of the biopharmaceutical company’s stock after selling 8,513 shares during the period. Hsbc Holdings PLC’s holdings in Dynavax Technologies were worth $236,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of DVAX. Nordea Investment Management AB lifted its position in Dynavax Technologies by 1.2% during the 3rd quarter. Nordea Investment Management AB now owns 161,391 shares of the biopharmaceutical company’s stock worth $1,695,000 after acquiring an additional 1,948 shares in the last quarter. Jackson Square Capital LLC acquired a new position in Dynavax Technologies during the 3rd quarter worth approximately $171,000. Creative Financial Designs Inc. ADV lifted its position in Dynavax Technologies by 1,875.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 7,900 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 7,500 shares in the last quarter. KBC Group NV purchased a new stake in Dynavax Technologies during the 3rd quarter worth approximately $100,000. Finally, Simon Quick Advisors LLC increased its holdings in Dynavax Technologies by 9.0% during the 3rd quarter. Simon Quick Advisors LLC now owns 29,000 shares of the biopharmaceutical company’s stock worth $303,000 after purchasing an additional 2,400 shares during the last quarter. 94.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DVAX. JMP Securities lifted their price objective on Dynavax Technologies from $22.00 to $25.00 and gave the stock a “market outperform” rating in a report on Friday, February 24th. HC Wainwright dropped their price objective on Dynavax Technologies from $28.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, February 24th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.33.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, CAO Justin Burgess sold 22,371 shares of the stock in a transaction on Monday, February 27th. The stock was sold at an average price of $10.38, for a total value of $232,210.98. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 9.31% of the company’s stock.

Dynavax Technologies Trading Down 1.6 %

NASDAQ DVAX opened at $9.73 on Friday. The firm has a market capitalization of $1.24 billion, a PE ratio of 4.94 and a beta of 1.45. Dynavax Technologies Co. has a one year low of $7.26 and a one year high of $17.48. The company has a 50-day simple moving average of $10.96 and a 200-day simple moving average of $11.27. The company has a debt-to-equity ratio of 0.38, a quick ratio of 5.71 and a current ratio of 6.11.

Dynavax Technologies Profile

(Get Rating)

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.